UA73970C2 - Propofol formulation protected from bacterial growth - Google Patents
Propofol formulation protected from bacterial growth Download PDFInfo
- Publication number
- UA73970C2 UA73970C2 UA2002086807A UA2002086807A UA73970C2 UA 73970 C2 UA73970 C2 UA 73970C2 UA 2002086807 A UA2002086807 A UA 2002086807A UA 2002086807 A UA2002086807 A UA 2002086807A UA 73970 C2 UA73970 C2 UA 73970C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pharmaceutical composition
- propofol
- composition according
- sterile pharmaceutical
- fact
- Prior art date
Links
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 title claims abstract description 61
- 229960004134 propofol Drugs 0.000 title claims abstract description 61
- 239000000203 mixture Substances 0.000 title abstract description 83
- 238000009472 formulation Methods 0.000 title abstract description 17
- 230000001580 bacterial effect Effects 0.000 title description 5
- 235000012424 soybean oil Nutrition 0.000 claims abstract description 28
- 239000003549 soybean oil Substances 0.000 claims abstract description 28
- 239000008344 egg yolk phospholipid Substances 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000011109 contamination Methods 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 4
- 210000004369 blood Anatomy 0.000 claims abstract description 4
- 239000002904 solvent Substances 0.000 claims description 18
- 239000004094 surface-active agent Substances 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 239000008215 water for injection Substances 0.000 claims description 5
- -1 fatty acid ester Chemical class 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 abstract description 19
- 239000003755 preservative agent Substances 0.000 abstract description 9
- 230000000845 anti-microbial effect Effects 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 4
- 230000002335 preservative effect Effects 0.000 abstract description 4
- 206010039897 Sedation Diseases 0.000 abstract description 2
- 230000036280 sedation Effects 0.000 abstract description 2
- 230000001684 chronic effect Effects 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000003921 oil Substances 0.000 description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
- 230000000813 microbial effect Effects 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- OUDSFQBUEBFSPS-UHFFFAOYSA-N ethylenediaminetriacetic acid Chemical compound OC(=O)CNCCN(CC(O)=O)CC(O)=O OUDSFQBUEBFSPS-UHFFFAOYSA-N 0.000 description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 239000007764 o/w emulsion Substances 0.000 description 5
- 230000001624 sedative effect Effects 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000002695 general anesthesia Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 235000019445 benzyl alcohol Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 229940067082 pentetate Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000538132 Moya Species 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000004213 low-fat Nutrition 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000004045 soybean oil emulsion Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/745,018 US6399087B1 (en) | 2000-12-20 | 2000-12-20 | Propofol formulation with enhanced microbial inhibition |
PCT/US2001/022248 WO2002049631A1 (en) | 2000-12-20 | 2001-07-16 | Propofol formulation with enhanced microbial inhibition |
Publications (1)
Publication Number | Publication Date |
---|---|
UA73970C2 true UA73970C2 (en) | 2005-10-17 |
Family
ID=24994883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA2002086807A UA73970C2 (en) | 2000-12-20 | 2001-07-16 | Propofol formulation protected from bacterial growth |
Country Status (11)
Country | Link |
---|---|
US (1) | US6399087B1 (zh) |
EP (1) | EP1250130A4 (zh) |
JP (1) | JP2004516265A (zh) |
CN (1) | CN1359677A (zh) |
AU (1) | AU7592501A (zh) |
BR (1) | BR0109769A (zh) |
CA (1) | CA2397990A1 (zh) |
MX (1) | MXPA02008097A (zh) |
RU (1) | RU2244545C2 (zh) |
UA (1) | UA73970C2 (zh) |
WO (1) | WO2002049631A1 (zh) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
JP4842514B2 (ja) * | 2002-03-20 | 2011-12-21 | エラン ファーマ インターナショナル,リミティド | 血管新生抑制剤のナノ粒子組成物 |
US20080220075A1 (en) * | 2002-03-20 | 2008-09-11 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
CA2503956A1 (en) * | 2002-10-29 | 2004-05-13 | Transform Pharmaceuticals, Inc. | Propofol with cysteine |
TR200502189T1 (tr) * | 2002-12-09 | 2007-01-22 | American Bioscience, Inc. | Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler. |
US7468394B1 (en) * | 2003-03-11 | 2008-12-23 | Amphastar Pharmaceuticals, Inc. | Sterile pharmaceutical composition and process for a solution of propofol emulsion having microbial growth retardation |
US20040225022A1 (en) * | 2003-05-09 | 2004-11-11 | Desai Neil P. | Propofol formulation containing reduced oil and surfactants |
US8476010B2 (en) * | 2003-07-10 | 2013-07-02 | App Pharmaceuticals Llc | Propofol formulations with non-reactive container closures |
US8546453B2 (en) * | 2003-08-14 | 2013-10-01 | Rensheng Zhang | Propofol compositions and methods for reducing pain associated with propofol injection |
ES2719093T3 (es) * | 2005-08-31 | 2019-07-08 | Abraxis Bioscience Llc | Composiciones de fármacos poco solubles en agua con mayor estabilidad y métodos para su preparación |
BRPI0615265A8 (pt) * | 2005-08-31 | 2018-03-06 | Abraxis Bioscience Llc | composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos |
CN101411685B (zh) * | 2007-10-19 | 2011-04-20 | 上海医药工业研究院 | 一种静脉麻醉药2,6-二异丙基苯酚微乳组合物及其制备方法 |
KR101656121B1 (ko) | 2010-03-17 | 2016-09-08 | 노바리크 게엠베하 | 안압 증가를 치료하기 위한 약학 조성물 |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
DK2661280T3 (en) * | 2011-01-04 | 2019-03-04 | Novaliq Gmbh | O / V EMULSIONS INCLUDING SEMIFLUORINATED ALKANES |
RS54711B1 (en) * | 2011-03-04 | 2016-08-31 | Grünenthal GmbH | PARENTERAL TAPENTADOL ADMINISTRATION |
PT3287123T (pt) | 2011-03-04 | 2020-05-22 | Gruenenthal Gmbh | Formulação farmacêutica aquosa de tapentadol para administração oral |
JP2019142972A (ja) * | 2011-03-04 | 2019-08-29 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | タペンタドールの非経口的投与 |
KR102039320B1 (ko) | 2011-03-04 | 2019-11-01 | 그뤼넨탈 게엠베하 | 타펜타돌을 함유하는 반고체 수성 약제학적 조성물 |
CN103596554A (zh) | 2011-05-25 | 2014-02-19 | 诺瓦利克有限责任公司 | 基于半氟化烷烃类的外用药物组合物 |
JP2013001700A (ja) * | 2011-06-21 | 2013-01-07 | Fujifilm Corp | プロポフォール含有水中油型エマルション組成物 |
JP5759804B2 (ja) * | 2011-06-27 | 2015-08-05 | 富士フイルム株式会社 | 容器詰製剤 |
PL2806886T3 (pl) | 2012-01-23 | 2017-08-31 | Novaliq Gmbh | Stabilizowane kompozycje białkowe oparte na semifluorowanych alkanach |
MX2014013826A (es) | 2012-05-16 | 2018-04-24 | Singh Mewa | Composiciones farmaceuticas para la entrega de farmacos sustancialmente solubles en agua. |
EP3488847B1 (en) | 2012-09-12 | 2023-11-08 | Novaliq GmbH | Semifluorinated alkane compositions |
CN106511322B (zh) | 2012-09-12 | 2021-09-17 | 诺瓦利克有限责任公司 | 包含半氟化烷烃的混合物的组合物 |
MX370207B (es) | 2013-07-23 | 2019-12-05 | Novaliq Gmbh | Composiciones estabilizadas de anticuerpos. |
PL3273953T3 (pl) | 2015-03-27 | 2019-07-31 | Grünenthal GmbH | Stabilny preparat do pozajelitowego podawania tapentadolu |
EP3331567B1 (en) * | 2015-07-24 | 2020-09-23 | Neon Laboratories Ltd. | Stabilized injectable emulsion of propofol and ketamine |
WO2017031261A1 (en) | 2015-08-20 | 2017-02-23 | Mewa Singh | Polyphenolic polymer to make water-insoluble molecules become water-soluble |
PL3355990T3 (pl) | 2015-09-30 | 2019-11-29 | Novaliq Gmbh | Semifluorowane związki oraz ich kompozycje |
JP6642935B2 (ja) | 2015-09-30 | 2020-02-12 | ノバリック ゲーエムベーハー | 眼投与用の半フッ素化化合物 |
JP2019520357A (ja) | 2016-06-23 | 2019-07-18 | ノバリック ゲーエムベーハー | 局所投与方法 |
AU2017329772B2 (en) | 2016-09-22 | 2023-02-02 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
ES2965677T3 (es) | 2016-09-23 | 2024-04-16 | Novaliq Gmbh | Composiciones oftálmicas que comprenden ciclosporina |
MX2019003257A (es) | 2016-09-23 | 2019-06-10 | Gruenenthal Gmbh | Formulacion estable para la administracion parenteral de tapentadol. |
WO2018193093A1 (en) | 2017-04-21 | 2018-10-25 | Novaliq Gmbh | Iodine compositions |
WO2018206656A1 (en) | 2017-05-12 | 2018-11-15 | Novaliq Gmbh | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
KR20200059272A (ko) | 2017-09-27 | 2020-05-28 | 노바리크 게엠베하 | 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물 |
WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
CA3091308A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL141095A0 (en) * | 1998-08-19 | 2002-02-10 | Rtp Pharma Inc | Injectable aqueous dispersions of propofol |
US6140374A (en) * | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
US6100302A (en) * | 1999-04-05 | 2000-08-08 | Baxter International Inc. | Propofol formulation with enhanced microbial characteristics |
-
2000
- 2000-12-20 US US09/745,018 patent/US6399087B1/en not_active Expired - Lifetime
-
2001
- 2001-07-16 EP EP01953482A patent/EP1250130A4/en not_active Withdrawn
- 2001-07-16 BR BR0109769-5A patent/BR0109769A/pt not_active IP Right Cessation
- 2001-07-16 WO PCT/US2001/022248 patent/WO2002049631A1/en active Application Filing
- 2001-07-16 AU AU7592501A patent/AU7592501A/xx not_active Withdrawn
- 2001-07-16 MX MXPA02008097A patent/MXPA02008097A/es active IP Right Grant
- 2001-07-16 UA UA2002086807A patent/UA73970C2/uk unknown
- 2001-07-16 RU RU2002122394/15A patent/RU2244545C2/ru not_active IP Right Cessation
- 2001-07-16 CA CA002397990A patent/CA2397990A1/en not_active Abandoned
- 2001-07-16 JP JP2002550973A patent/JP2004516265A/ja active Pending
- 2001-09-21 CN CN01141917A patent/CN1359677A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1250130A1 (en) | 2002-10-23 |
WO2002049631A1 (en) | 2002-06-27 |
MXPA02008097A (es) | 2004-09-10 |
BR0109769A (pt) | 2003-02-04 |
RU2002122394A (ru) | 2004-03-20 |
CN1359677A (zh) | 2002-07-24 |
RU2244545C2 (ru) | 2005-01-20 |
US6399087B1 (en) | 2002-06-04 |
AU7592501A (en) | 2002-07-01 |
JP2004516265A (ja) | 2004-06-03 |
CA2397990A1 (en) | 2002-06-27 |
EP1250130A4 (en) | 2006-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA73970C2 (en) | Propofol formulation protected from bacterial growth | |
AU774259B2 (en) | Propofol formulation with enhanced microbial characteristics | |
EP1124536B1 (en) | Propofol composition comprising pentetate | |
US6147122A (en) | Propofol composition containing sulfite | |
FI120641B (fi) | Ruuansulatuskanavan ulkopuolisesti annettavat rasvaemulsiot, jotka sisältävät edetaattia säilöntäaineena | |
EP1163007B1 (en) | Propofol formulation containing tris | |
AU2001275925B2 (en) | Propofol formulation with enhanced microbial inhibition | |
CA2366799A1 (en) | Propofol compositions containing preservative additives | |
MXPA01004004A (en) | Propofol composition comprising pentetate |